Abbott Laboratories (ABT) Stock Forecast & Price Target

$126.84 +2.34 (+1.88%)

Closing price 04/11/2025 03:59 PM Eastern

Extended Trading

$127.29 +0.45 (+0.36%)

As of 09:07 AM Eastern

Abbott Laboratories - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 19 Analyst Ratings

Sell
0

Hold
4

Buy
15

Based on 19 Wall Street analysts who have issued ratings for Abbott Laboratories in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 19 analysts, 4 have given a hold rating, 14 have given a buy rating, and 1 has given a strong buy rating for ABT.

Consensus Price Target

$137.94
8.75% Upside

According to the 19 analysts' twelve-month price targets for Abbott Laboratories, the average price target is $137.94. The highest price target for ABT is $160.00, while the lowest price target for ABT is $117.00. The average price target represents a forecasted upside of 8.75% from the current price of $126.84.

Get the Latest News and Ratings for ABT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Abbott Laboratories and its competitors.

ABT Analyst Ratings Over Time

Type	Current Forecast 4/14/24 to 4/14/25	1 Month Ago 3/15/24 to 3/15/25	3 Months Ago 1/15/24 to 1/14/25	1 Year Ago 4/15/23 to 4/14/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	14 Buy rating(s)	14 Buy rating(s)	11 Buy rating(s)	10 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$137.94	$137.94	$131.57	$122.14
Forecasted Upside	8.75% Upside	8.60% Upside	16.47% Upside	11.94% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Remove Ads

ABT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ABT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Abbott Laboratories Stock vs. The Competition

Type	Abbott Laboratories	Medical Companies	S&P 500
Consensus Rating Score	2.84	2.82	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	8.75% Upside	21,704.78% Upside	27.84% Upside
News Sentiment Rating	Positive News See Recent ABT News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/10/2025	Bank of America 3 of 5 stars	Travis Steed Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$133.00 ➝ $150.00	+8.03%
3/4/2025	Citigroup 2 of 5 stars	Joanne Wuensch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$135.00 ➝ $160.00	+15.20%
3/4/2025	The Goldman Sachs Group 3 of 5 stars	David Roman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$138.00 ➝ $154.00	+9.70%
1/28/2025	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
1/27/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$149.00 ➝ $158.00	+26.28%
1/23/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$130.00 ➝ $135.00	+14.64%
1/23/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lawrence Biegelsen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$133.00 ➝ $136.00	+15.49%
1/23/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Danielle Antalffy Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$146.00 ➝ $148.00	+25.68%
1/21/2025	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$135.00 ➝ $135.00	+16.42%
1/2/2025	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$136.00	+19.76%
Get the Latest News and Ratings for ABT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Abbott Laboratories and its competitors with MarketBeat's FREE daily newsletter.
10/17/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$133.00 ➝ $138.00	+17.37%
10/17/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$120.00 ➝ $125.00	+5.91%
10/17/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$115.00 ➝ $130.00	+10.34%
10/17/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$107.00 ➝ $117.00	-0.70%
10/17/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Maeder Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$131.00 ➝ $133.00	+12.88%
10/14/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Buy	$122.00 ➝ $129.00	+10.28%
10/8/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$130.00	+14.69%
9/19/2024	Piper Sandler Companies Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$131.00	+14.04%
7/30/2024	Edward Jones Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
7/21/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underperform ➝ Peer Perform
4/20/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight	$118.00 ➝ $122.00	+9.56%
4/17/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$125.00 ➝ $130.00	+25.05%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 09:07 AM ET.

Should I Buy Abbott Laboratories Stock? ABT Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 9, 2025. Please send any questions or comments about these Abbott Laboratories pros and cons to contact@marketbeat.com.

Abbott Laboratories
Bull Case

Here are some ways that investors could benefit from investing in Abbott Laboratories:

Abbott Laboratories has received multiple upgrades from research firms, with price targets now reaching as high as $158.00, indicating strong market confidence in the company's growth potential.
The company has a solid payout ratio of 30.85%, suggesting a commitment to returning value to shareholders through dividends while still retaining enough earnings for growth.
Recent insider trading shows that a senior vice president recently sold shares but still holds a significant stake, indicating confidence in the company's future performance.
Abbott Laboratories operates in diverse segments, including Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices, which helps mitigate risks associated with reliance on a single market.
The current stock price is approximately $135.00, which is within the range of recent analyst price targets, suggesting potential for appreciation as the market recognizes the company's value.

Abbott Laboratories
Bear Case

Investors should be bearish about investing in Abbott Laboratories for these reasons:

Despite positive ratings, the stock has seen insider selling, with over 116,000 shares sold in the last 90 days, which could signal a lack of confidence among some insiders.
Hedge fund ownership is high at 75.18%, which can lead to volatility if these institutional investors decide to sell off their positions quickly.
While the company has a strong product portfolio, it faces intense competition in the healthcare sector, which could impact market share and profitability.
The recent increase in price targets may lead to overvaluation concerns, especially if the company fails to meet the high expectations set by analysts.
Market conditions can be unpredictable, and any economic downturn could adversely affect Abbott Laboratories' sales across its various segments.

ABT Forecast - Frequently Asked Questions

: According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Abbott Laboratories is $137.94, with a high forecast of $160.00 and a low forecast of $117.00.
: 19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last twelve months. There are currently 4 hold ratings, 14 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ABT shares.
: According to analysts, Abbott Laboratories's stock has a predicted upside of 8.75% based on their 12-month stock forecasts.
: Over the previous 90 days, Abbott Laboratories's stock had 1 upgrade by analysts.
: Abbott Laboratories has been rated by research analysts at Argus, Bank of America, Barclays, Citigroup, Royal Bank of Canada, Stifel Nicolaus, The Goldman Sachs Group, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like Abbott Laboratories more than other "medical" companies. The consensus rating score for Abbott Laboratories is 2.84 while the average consensus rating score for "medical" companies is 2.82. Learn more on how ABT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:ABT) was last updated on 4/14/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abbott Laboratories (ABT) Stock Forecast & Price Target